Tubulis and Gilead Sciences have announced an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.
Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms. The two companies will collaborate on the selection of the most appropriate technology, with Tubulis leading the discovery and development efforts to design a Topoisomerase I inhibitor-based ADC candidate.
Under the terms of the agreement, Tubulis will receive an upfront payment of $20 million and, if Gilead exercises its option, a separate option exercise fee of $30 million. In addition, Tubulis is eligible to receive development and commercialization milestone payments totaling up to $415 million, plus royalties.
More information in the press release under the following link
More about Tubulis
